HU Mengyu, YANG Yubing, SHI Yiling, GUO Shiduo, YANG Wanting, ZHANG Xinzhuang, CAO Liang, XIAO Wei, WU Ziyin, WANG Zhenzhong
Chinese Traditional and Herbal Drugs. 2026, 57(9): 3429-3444.
Objective To systematically evaluate the therapeutic effects of Jinzhen Oral Liquid (金振口服液, JZOL) on a pathological model of chronic obstructive pulmonary disease (COPD) complicated with phlegm-heat syndrome, and to elucidate its pharmacological mechanisms from multiple dimensions, including improvement of pulmonary function, suppression of systemic inflammation, regulation of airway mucus secretion, restoration of Th1/Th2 and Th17/Treg immune balance, and modulation of transcriptomic expression profiles. Methods A rat COPD model was established through eight weeks of cigarette smoke exposure combined with intranasal lipopolysaccharide (LPS) instillation. Subsequently, a compound model of COPD with phlegm-heat syndrome was induced by 9 d of wind-heat exposure combined with LPS instillation. Model rats were randomly assigned to model group, dexamethasone (0.2 mg/kg) group and JZOL low-, medium-, high-dose (0.8, 1.6, 3.2 g/kg) groups, and received continuous oral administration for 7 d. Therapeutic efficacy was comprehensively evaluated by assessing pulmonary function parameters, systemic symptoms and signs, inflammatory factors in serum, lung histopathological changes and proportions of lung T cell subsets in lung tissue. Furthermore, transcriptomic sequencing and qRT-PCR were employed to validate the regulatory effects of JZOL on key differentially expressed genes, including lipocalin-2 (Lcn2), indoleamine 2,3-dioxygenase 1 (Ido1), cyclin E1 (Ccne1), homeobox protein B8 (Hoxb8) and G protein-coupled receptor 17 (Gpr17). Results The compound modeling successfully induced severe airflow limitation, fever, constipation, and histopathological and cytopathological alterations in rats. Compared with model group, JZOL significantly improved lung function (P < 0.05, 0.01, 0.001), significantly reduced levels of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), C-reactive protein (CRP) and neutrophil elastase (NE) in serum (P < 0.001), significantly reduced bronchial epithelial goblet cell proliferation and acid mucin secretion (P < 0.05, 0.001), and corrected imbalanced Th1/Th2 and Th17/Treg cells ratios (P < 0.05, 0.001). The transcriptome and qRT-PCR validation results showed that JZOL improved COPD through multiple mechanisms, including downregulation of immune microenvironment and protease imbalance related genes, inhibition of abnormal cell cycle and airway remodeling genes, upregulation of key lung regeneration factors and regulation of developmental factors, as well as activation of tissue repair and inflammation resolution pathways. Conclusion JZOL effectively improves lung function and systemic symptoms in COPD rats with phlegm heat syndrome by inhibiting systemic and local inflammatory responses through multiple targets, regulating T cell immune balance.